药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Lumiracoxib
CUDC-101
The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Vemurafenib.
Lumiracoxib
Entinostat
The risk or severity of QTc prolongation can be increased when Entinostat is combined with Vemurafenib.
Lumiracoxib
Mocetinostat
The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Vemurafenib.
Lumiracoxib
Amifampridine
The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Vemurafenib.
Lumiracoxib
Dexchlorpheniramine maleate
The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Vemurafenib.
Lumiracoxib
Melperone
The risk or severity of QTc prolongation can be increased when Melperone is combined with Vemurafenib.
Lumiracoxib
Butriptyline
The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Vemurafenib.
Lumiracoxib
Eperisone
The risk or severity of QTc prolongation can be increased when Eperisone is combined with Vemurafenib.
Lumiracoxib
Fendiline
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Vemurafenib.
Lumiracoxib
Bedaquiline
The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Vemurafenib.
Lumiracoxib
Antazoline
The risk or severity of QTc prolongation can be increased when Antazoline is combined with Vemurafenib.
Lumiracoxib
Nemonoxacin
The risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Vemurafenib.
Lumiracoxib
Telavancin
The risk or severity of QTc prolongation can be increased when Telavancin is combined with Vemurafenib.
Lumiracoxib
Tucidinostat
The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Vemurafenib.
Lumiracoxib
Tedisamil
The risk or severity of QTc prolongation can be increased when Tedisamil is combined with Vemurafenib.
Lumiracoxib
Garenoxacin
The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Vemurafenib.
Lumiracoxib
Technetium Tc-99m ciprofloxacin
The risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Vemurafenib.
Lumiracoxib
Pracinostat
The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Vemurafenib.
Lumiracoxib
Azimilide
The risk or severity of QTc prolongation can be increased when Azimilide is combined with Vemurafenib.
Lumiracoxib
Fluspirilene
The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Vemurafenib.